Modality
Gene Editing
MOA
SOS1i
Target
KRASG12C
Pathway
Apoptosis
HNSCC
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
~Nov 2019
→ ~Feb 2021
Phase 2
~May 2021
→ ~Aug 2022
Phase 3
Nov 2022
→ Jan 2027
Phase 3Current
NCT06892514
2,162 pts·HNSCC
2022-11→2027-01·Active
2,162 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-1910mo awayPh3 Readout· HNSCC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P3
Active
Catalysts
Ph3 Readout
2027-01-19 · 10mo away
HNSCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06892514 | Phase 3 | HNSCC | Active | 2162 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |